Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 69
Filter
1.
Biochem Pharmacol ; 197: 114871, 2022 03.
Article in English | MEDLINE | ID: mdl-34902340

ABSTRACT

Stereoselectivity is important in many pharmacological processes but its impact on drug membrane transport is scarcely understood. Recent studies showed strong stereoselective effects in the cellular uptake of fenoterol by the organic cation transporters OCT1 and OCT2. To provide possible molecular explanations, homology models were developed and the putative interactions between fenoterol enantiomers and key residues explored in silico through computational docking, molecular dynamics simulations, and binding free energy calculations as well as in vitro by site-directed mutagenesis and cellular uptake assays. Our results suggest that the observed 1.9-fold higher maximum transport velocity (vmax) for (R,R)- over (S,S)-fenoterol in OCT1 is because the enantiomers bind to two distinct binding sites. Mutating PHE355 and ILE442, predicted to interact with (R,R)-fenoterol, reduced the vmax ratio to 1.5 and 1.3, respectively, and to 1.2 in combination. Mutating THR272, predicted to interact with (S,S)-fenoterol, slightly increased stereoselectivity (vmax ratio of 2.2), while F244A resulted in a 35-fold increase in vmax and a lower affinity (29-fold higher Km) for (S,S)-fenoterol. Both enantiomers of salbutamol, for which almost no stereoselectivity was observed, were predicted to occupy the same binding pocket as (R,R)-fenoterol. Unlike for OCT1, both fenoterol enantiomers bind in the same region in OCT2 but in different conformations. Mutating THR246, predicted to interact with (S,S)-fenoterol in OCT2, led to an 11-fold decreased vmax. Altogether, our mutagenesis results correlate relatively well with our computational predictions and thereby provide an experimentally-corroborated hypothesis for the strong and contrasting enantiopreference in fenoterol uptake by OCT1 and OCT2.


Subject(s)
Fenoterol/chemistry , Fenoterol/metabolism , Octamer Transcription Factor-1/chemistry , Octamer Transcription Factor-1/metabolism , Organic Cation Transporter 2/chemistry , Organic Cation Transporter 2/metabolism , Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Biological Transport/physiology , HEK293 Cells , Humans , Molecular Docking Simulation/methods , Mutagenesis, Site-Directed/methods , Octamer Transcription Factor-1/genetics , Organic Cation Transporter 2/genetics , Point Mutation/genetics , Protein Structure, Secondary , Stereoisomerism
2.
Mol Pharmacol ; 100(4): 406-427, 2021 10.
Article in English | MEDLINE | ID: mdl-34334369

ABSTRACT

The drugs salmeterol, formoterol, and salbutamol constitute the frontline treatment of asthma and other chronic pulmonary diseases. These drugs activate the ß2-adrenergic receptors (ß2-AR), a class A G protein-coupled receptor (GPCR), and differ significantly in their clinical onset and duration of actions. According to the microkinetic model, the long duration of action of salmeterol and formoterol compared with salbutamol were attributed, at least in part, to their high lipophilicity and increased local concentrations in the membrane near the receptor. However, the structural and molecular bases of how the lipophilic drugs reach the binding site of the receptor from the surrounding membrane remain unknown. Using a variety of classic and enhanced molecular dynamics simulation techniques, we investigated the membrane partitioning characteristics, binding, and unbinding mechanisms of the ligands. The obtained results offer remarkable insight into the functional role of membrane lipids in the ligand association process. Strikingly, salmeterol entered the binding site from the bilayer through transmembrane helices 1 and 7. The entry was preceded by membrane-facilitated rearrangement and presentation of its phenyl-alkoxy-alkyl tail as a passkey to an access route gated by F193, a residue known to be critical for salmeterol's affinity. Formoterol's access is through the aqueous path shared by other ß2-AR agents. We observed a novel secondary path for salbutamol that is distinct from its primary route. Our study offers a mechanistic description for the membrane-facilitated access and binding of ligands to a membrane protein and establishes a groundwork for recognizing membrane lipids as an integral component in the molecular recognition process. SIGNIFICANCE STATEMENT: The cell membrane's functional role behind the duration of action of long-acting ß2-adrenergic receptor (ß2-AR) agonists such as salmeterol has been a subject of debate for a long time. This study investigated the binding and unbinding mechanisms of the three commonly used ß2-AR agonists, salmeterol, formoterol, and salbutamol, using advanced simulation techniques. The obtained results offer unprecedented insights into the active role of membrane lipids in facilitating access and binding of the ligands, affecting the molecular recognition process and thus their pharmacology.


Subject(s)
Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Cell Membrane/metabolism , Molecular Docking Simulation/methods , Albuterol/chemistry , Albuterol/metabolism , Binding Sites/physiology , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/metabolism , Formoterol Fumarate/chemistry , Formoterol Fumarate/metabolism , Humans , Protein Binding/physiology , Protein Structure, Secondary , Protein Structure, Tertiary , Salmeterol Xinafoate/chemistry , Salmeterol Xinafoate/metabolism
3.
Biochemistry ; 59(7): 880-891, 2020 02 25.
Article in English | MEDLINE | ID: mdl-31999436

ABSTRACT

Agonist binding to G protein-coupled receptors (GPCRs) leads to conformational changes in the transmembrane region that activate cytosolic signaling pathways. Although high-resolution structures of different receptor states are available, atomistic details of allosteric signaling across the membrane remain elusive. We calculated free energy landscapes of ß2 adrenergic receptor activation using atomistic molecular dynamics simulations in an optimized string of swarms framework, which shed new light on how microswitches govern the equilibrium between conformational states. Contraction of the extracellular binding site in the presence of the agonist BI-167107 is obligatorily coupled to conformational changes in a connector motif located in the core of the transmembrane region. The connector is probabilistically coupled to the conformation of the intracellular region. An active connector promotes desolvation of a buried cavity, a twist of the conserved NPxxY motif, and an interaction between two conserved tyrosines in transmembrane helices 5 and 7 (Y-Y motif), which lead to a larger population of active-like states at the G protein binding site. This coupling is augmented by protonation of the strongly conserved Asp792.50. The agonist binding site hence communicates with the intracellular region via a cascade of locally connected microswitches. Characterization of these can be used to understand how ligands stabilize distinct receptor states and contribute to development drugs with specific signaling properties. The developed simulation protocol can likely be transferred to other class A GPCRs.


Subject(s)
Adrenergic beta-2 Receptor Agonists/chemistry , Benzoxazines/chemistry , Protein Conformation/drug effects , Receptors, Adrenergic, beta-2/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Aspartic Acid/chemistry , Benzoxazines/metabolism , Binding Sites , Humans , Ligands , Molecular Dynamics Simulation , Receptors, Adrenergic, beta-2/metabolism , Sodium/chemistry , Sodium/metabolism , Thermodynamics
4.
Mol Pharmacol ; 96(6): 851-861, 2019 12.
Article in English | MEDLINE | ID: mdl-31624135

ABSTRACT

G protein-coupled receptors exist in a whole spectrum of conformations that are stabilized by the binding of ligands with different efficacy or intracellular effector proteins. Here, we investigate whether three-dimensional structures of receptor conformations in different states of activation can be used to enrich ligands with agonist behavior in prospective docking calculations. We focused on the ß 2-adrenergic receptor, as it is currently the receptor with the highest number of active-state crystal structures. Comparative docking calculations to distinct conformations of the receptor were used for the in silico prediction of ligands with agonist efficacy. The pharmacology of molecules selected based on these predictions was characterized experimentally, resulting in a hit rate of 37% ligands, all of which were agonists. The ligands furthermore contain a pyrazole moiety that has previously not been described for ß 2-adrenergic receptor ligands, and one of them shows an intrinsic efficacy comparable to salbutamol. SIGNIFICANCE STATEMENT: Structure-based ligand design for G protein-coupled receptors crucially depends on receptor conformation and, hence, their activation state. We explored the influence of using multiple active-conformation X-ray structures on the hit rate of docking calculations to find novel agonists, and how to predict the most fruitful strategy to apply. The results suggest that aggregating the ranks of molecules across docking calculations to more than one active-state structure exclusively yields agonists.


Subject(s)
Adrenergic beta-2 Receptor Agonists/metabolism , Adrenergic beta-2 Receptor Agonists/pharmacology , Molecular Docking Simulation/methods , Receptors, Adrenergic, beta-2/chemistry , Receptors, Adrenergic, beta-2/metabolism , Animals , CHO Cells , Cricetinae , Cricetulus , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Ligands , Protein Conformation , Protein Structure, Secondary , Receptors, G-Protein-Coupled/agonists
5.
Chem Biol Drug Des ; 93(5): 883-899, 2019 05.
Article in English | MEDLINE | ID: mdl-30637937

ABSTRACT

This study investigates the structural distinctiveness of orthosteric ligand-binding sites of several human ß2 adrenergic receptor (ß2 -AR) conformations that have been obtained from a set of independent molecular dynamics (MD) simulations in the presence of intracellular loop 3 (ICL3). A docking protocol was established in order to classify each receptor conformation via its binding affinity to selected ligands with known efficacy. This work's main goal was to reveal many subtle features of the ligand-binding site, presenting alternative conformations, which might be considered as either active- or inactive-like but mostly specific for that ligand. Agonists, inverse agonists, and antagonists were docked to each MD conformer with distinct binding pockets, using different docking tools and scoring functions. Mostly favored receptor conformation persistently observed in all docking/scoring evaluations was classified as active or inactive based on the type of ligand's biological effect. Classified MD conformers were further tested for their ability to discriminate agonists from inverse agonists/antagonists, and several conformers were proposed as important targets to be used in virtual screening experiments that were often limited to a single X-ray structure.


Subject(s)
Ligands , Molecular Docking Simulation , Molecular Dynamics Simulation , Receptors, Adrenergic, beta-2/chemistry , Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Adrenergic beta-2 Receptor Antagonists/chemistry , Adrenergic beta-2 Receptor Antagonists/metabolism , Area Under Curve , Binding Sites , Cluster Analysis , Crystallography, X-Ray , Drug Inverse Agonism , Humans , Protein Structure, Tertiary , ROC Curve , Receptors, Adrenergic, beta-2/metabolism
6.
Eur Biophys J ; 48(1): 83-97, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30386878

ABSTRACT

The design of beta2 adrenoceptor (ß2AR) agonists is attractive because of their wide-ranging applications in medicine, and the details of agonist interactions with ß2AR are interesting because it is considered a prototype for G-protein coupled receptors. Preclinical studies for agonist development have involved biological assays with guinea pigs due to a similar physiology to humans. Boron-containing Albuterol derivatives (BCADs) designed as bronchodilators have improved potency and efficacy compared with their boron-free precursor on guinea pig ß2ARs (gpß2ARs), and two of the BCADs (BR-AEA and boronterol) conserve these features on cells expressing human ß2ARs (hß2ARs). The aim of this study was to test the BCAD Politerol on gpß2ARs and hß2ARs in vitro and in silico. Politerol displayed higher potency and efficacy on gpß2AR than on hß2AR in experimental assays, possible explanations are provided based on molecular modeling, and molecular dynamics simulations of about 0.25 µs were performed for the free and bound states adding up to 2 µs in total. There were slight differences, particularly in the role of the boron atom, in the interactions of Politerol with gpß2ARs and hß2ARs, affecting movements of transmembrane domains 5-7, known to be pivotal in receptor activation. These findings could be instrumental in the design of compounds selective for hß2ARs.


Subject(s)
Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Boron Compounds/chemistry , Boron Compounds/metabolism , Molecular Dynamics Simulation , Receptors, Adrenergic, beta-2/metabolism , Animals , CHO Cells , Cricetulus , Guinea Pigs , Humans , Molecular Docking Simulation , Protein Binding , Protein Conformation , Receptors, Adrenergic, beta-2/chemistry , Thermodynamics
7.
Bioorg Med Chem ; 27(12): 2306-2314, 2019 06 15.
Article in English | MEDLINE | ID: mdl-30392952

ABSTRACT

A series of novel ß2-adrenoceptor agonists with a 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one moiety was designed, synthesized and evaluated for biological activity in human embryonic kidney 293 cells and isolated guinea pig trachea. Compounds 9g and (R)-18c exhibited the most excellent ß2-adrenoceptor agonistic effects and high ß2/ß1-selectivity with EC50 values of 36 pM for 9g and 21 pM for (R)-18c. They produced potent airway smooth muscle relaxant effects with fast onset of action and long duration of action in an in vitro guinea pig trachea model of bronchodilation. These results support further development of the two compounds into drug candidates.


Subject(s)
Adrenergic beta-2 Receptor Agonists/pharmacology , Bronchodilator Agents/pharmacology , Ethanolamines/pharmacology , Hydroxyquinolines/pharmacology , Adrenergic beta-2 Receptor Agonists/chemical synthesis , Adrenergic beta-2 Receptor Agonists/metabolism , Animals , Binding Sites , Bronchodilator Agents/chemical synthesis , Bronchodilator Agents/metabolism , Drug Design , Ethanolamines/chemical synthesis , Ethanolamines/metabolism , Guinea Pigs , HEK293 Cells , Humans , Hydroxyquinolines/chemical synthesis , Hydroxyquinolines/metabolism , Male , Molecular Docking Simulation , Receptors, Adrenergic, beta-2/chemistry , Receptors, Adrenergic, beta-2/metabolism , Trachea/drug effects
9.
Mol Pharmacol ; 94(3): 1031-1046, 2018 09.
Article in English | MEDLINE | ID: mdl-29959223

ABSTRACT

In asthma, the clinical efficacy of inhaled corticosteroids (ICSs) is enhanced by long-acting ß2-adrenoceptor agonists (LABAs). ICSs, or more accurately, glucocorticoids, promote therapeutically relevant changes in gene expression, and, in primary human bronchial epithelial cells (pHBECs) and airway smooth muscle cells, this genomic effect can be enhanced by a LABA. Modeling this interaction in human bronchial airway epithelial BEAS-2B cells transfected with a 2× glucocorticoid response element (2×GRE)-driven luciferase reporter showed glucocorticoid-induced transcription to be enhanced 2- to 3-fold by LABA. This glucocorticoid receptor (GR; NR3C1)-dependent effect occurred rapidly, was insensitive to protein synthesis inhibition, and was maximal when glucocorticoid and LABA were added concurrently. The ability of LABA to enhance GR-mediated transcription was not associated with changes in GR expression, serine (Ser203, Ser211, Ser226) phosphorylation, ligand affinity, or nuclear translocation. Chromatin immunoprecipitation demonstrated that glucocorticoid-induced recruitment of GR to the integrated 2×GRE reporter and multiple gene loci, whose mRNAs were unaffected or enhanced by LABA, was also unchanged by LABA. Transcriptomic analysis revealed glucocorticoid-induced mRNAs were variably enhanced, unaffected, or repressed by LABA. Thus, events leading to GR binding at target genes are not the primary explanation for how LABAs modulate GR-mediated transcription. As many glucocorticoid-induced genes are independently induced by LABA, gene-specific control by GR- and LABA-activated transcription factors may explain these observations. Because LABAs promote similar effects in pHBECs, therapeutic relevance is likely. These data illustrate the need to understand gene function(s), and the mechanisms leading to gene-specific induction, if existing ICS/LABA combination therapies are to be improved.


Subject(s)
Adrenergic beta-2 Receptor Agonists/metabolism , Receptors, Glucocorticoid/agonists , Receptors, Glucocorticoid/metabolism , Respiratory Mucosa/metabolism , Transcription, Genetic/physiology , Adrenergic beta-2 Receptor Agonists/pharmacology , Cells, Cultured , Delayed-Action Preparations , Dose-Response Relationship, Drug , Humans , Receptors, Glucocorticoid/genetics , Respiratory Mucosa/drug effects , Transcription, Genetic/drug effects
10.
Mol Pharmacol ; 94(2): 850-861, 2018 08.
Article in English | MEDLINE | ID: mdl-29769246

ABSTRACT

Conventional drug discovery efforts at the ß2-adrenoceptor (ß2AR) have led to the development of ligands that bind almost exclusively to the receptor's hormone-binding orthosteric site. However, targeting the largely unexplored and evolutionarily unique allosteric sites has potential for developing more specific drugs with fewer side effects than orthosteric ligands. Using our recently developed approach for screening G protein-coupled receptors (GPCRs) with DNA-encoded small-molecule libraries, we have discovered and characterized the first ß2AR small-molecule positive allosteric modulators (PAMs)-compound (Cmpd)-6 [(R)-N-(4-amino-1-(4-(tert-butyl)phenyl)-4-oxobutan-2-yl)-5-(N-isopropyl-N-methylsulfamoyl)-2-((4-methoxyphenyl)thio)benzamide] and its analogs. We used purified human ß2ARs, occupied by a high-affinity agonist, for the affinity-based screening of over 500 million distinct library compounds, which yielded Cmpd-6. It exhibits a low micro-molar affinity for the agonist-occupied ß2AR and displays positive cooperativity with orthosteric agonists, thereby enhancing their binding to the receptor and ability to stabilize its active state. Cmpd-6 is cooperative with G protein and ß-arrestin1 (a.k.a. arrestin2) to stabilize high-affinity, agonist-bound active states of the ß2AR and potentiates downstream cAMP production and receptor recruitment of ß-arrestin2 (a.k.a. arrestin3). Cmpd-6 is specific for the ß2AR compared with the closely related ß1AR. Structure-activity studies of select Cmpd-6 analogs defined the chemical groups that are critical for its biologic activity. We thus introduce the first small-molecule PAMs for the ß2AR, which may serve as a lead molecule for the development of novel therapeutics. The approach described in this work establishes a broadly applicable proof-of-concept strategy for affinity-based discovery of small-molecule allosteric compounds targeting unique conformational states of GPCRs.


Subject(s)
Adrenergic beta-2 Receptor Agonists/metabolism , Receptors, Adrenergic, beta-2/chemistry , Receptors, Adrenergic, beta-2/metabolism , Small Molecule Libraries/pharmacology , Allosteric Regulation/drug effects , Allosteric Site/drug effects , Drug Synergism , GTP-Binding Proteins/metabolism , Gene Library , Molecular Structure , Small Molecule Libraries/chemistry , Structure-Activity Relationship , Substrate Specificity , beta-Arrestin 1/metabolism
11.
Drug Deliv ; 25(1): 838-845, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29587546

ABSTRACT

Treatment of respiratory disease with a drug delivered via inhalation is generally held as being beneficial as it provides direct access to the lung target site with a minimum systemic exposure. There is however only limited information of the regional localization of drug retention following inhalation. The aim of this study was to investigate the regional and histological localization of salmeterol retention in the lungs after inhalation and to compare it to systemic administration. Lung distribution of salmeterol delivered to rats via nebulization or intravenous (IV) injection was analyzed with high-resolution mass spectrometry imaging (MSI). Salmeterol was widely distributed in the entire section at 5 min after inhalation, by 15 min it was preferentially retained in bronchial tissue. Via a novel dual-isotope study, where salmeterol was delivered via inhalation and d3-salmeterol via IV to the same rat, could the effective gain in drug concentration associated with inhaled delivery relative to IV, expressed as a site-specific lung targeting factor, was 5-, 31-, and 45-fold for the alveolar region, bronchial sub-epithelium and epithelium, respectively. We anticipate that this MSI-based framework for quantifying regional and histological lung targeting by inhalation will accelerate discovery and development of local and more precise treatments of respiratory disease.


Subject(s)
Adrenergic beta-2 Receptor Agonists/administration & dosage , Bronchi/metabolism , Bronchodilator Agents/administration & dosage , Lung/metabolism , Pulmonary Alveoli/metabolism , Respiratory Mucosa/metabolism , Salmeterol Xinafoate/administration & dosage , Administration, Inhalation , Adrenergic beta-2 Receptor Agonists/metabolism , Adrenergic beta-2 Receptor Agonists/pharmacokinetics , Adrenergic beta-2 Receptor Agonists/pharmacology , Animals , Bronchi/cytology , Bronchi/diagnostic imaging , Bronchi/drug effects , Bronchodilator Agents/metabolism , Bronchodilator Agents/pharmacokinetics , Bronchodilator Agents/pharmacology , Cluster Analysis , Deuterium , Injections, Intravenous , Lung/cytology , Lung/diagnostic imaging , Lung/drug effects , Male , Mass Spectrometry , Molecular Imaging , Pharmaceutical Vehicles/chemistry , Phosphatidylethanolamines/chemistry , Polyethylene Glycols/chemistry , Polysorbates/chemistry , Pulmonary Alveoli/cytology , Pulmonary Alveoli/diagnostic imaging , Pulmonary Alveoli/drug effects , Rats, Wistar , Respiratory Mucosa/cytology , Respiratory Mucosa/diagnostic imaging , Respiratory Mucosa/drug effects , Respiratory Tract Absorption , Salmeterol Xinafoate/metabolism , Salmeterol Xinafoate/pharmacokinetics , Salmeterol Xinafoate/pharmacology , Tissue Distribution
12.
J Nat Prod ; 81(4): 768-777, 2018 04 27.
Article in English | MEDLINE | ID: mdl-29517238

ABSTRACT

Isoquinoline alkaloids possess a wide range of structural features and pharmaceutical activities and are promising drug candidates. Ten water-soluble catecholic isoquinolines were isolated from the medicinal plant Portulaca oleracea, including three new (1-3) and seven known compounds (4-10), along with the known catecholamines 11 and 12 and four other known compounds (13-16). A method of polyamide column chromatography using EtOAc-MeOH as the mobile phase was developed for the isolation of catecholic isoquinolines. Alkaloids 1-12 exhibited anti-inflammatory activities (EC50 = 18.0-497.7 µM) through inhibition of NO production in lipopolysaccharide-induced murine macrophage RAW 264.7 cells. Among these compounds, 11, 2, 5, 4, and 8 were more potent than was the positive control, 3,4-dihydroxybenzohydroxamic acid (EC50 = 82.4 µM), with EC50 values of 18.0, 18.1, 35.4, 36.3, and 58.7 µM, respectively. Additionally, at 100 µM, compounds 1-12 showed different degrees of ß2-adrenergic receptor (ß2-AR) agonist activity in the CHO-K1/GA15 cell line which stably expressed ß2-AR as detected by a calcium assay. The EC50 values of 2 and 10 were 5.1 µM and 87.9 nM, respectively.


Subject(s)
Adrenergic Agonists/pharmacology , Adrenergic beta-2 Receptor Agonists/metabolism , Anti-Inflammatory Agents/pharmacology , Isoquinolines/pharmacology , Portulaca/chemistry , Adrenergic Agonists/chemistry , Animals , Anti-Inflammatory Agents/chemistry , CHO Cells , Cell Line , Cricetulus , Isoquinolines/chemistry , Macrophages/drug effects , Macrophages/metabolism , Mice , Plant Extracts/chemistry , Plant Extracts/pharmacology , Plants, Medicinal/chemistry , RAW 264.7 Cells
13.
Mol Pharmacol ; 93(4): 288-296, 2018 04.
Article in English | MEDLINE | ID: mdl-29367258

ABSTRACT

G-protein-coupled receptors (GPCRs) mediate multiple signaling pathways in the cell, depending on the agonist that activates the receptor and multiple cellular factors. Agonists that show higher potency to specific signaling pathways over others are known as "biased agonists" and have been shown to have better therapeutic index. Although biased agonists are desirable, their design poses several challenges to date. The number of assays to identify biased agonists seems expensive and tedious. Therefore, computational methods that can reliably calculate the possible bias of various ligands ahead of experiments and provide guidance, will be both cost and time effective. In this work, using the mechanism of allosteric communication from the extracellular region to the intracellular transducer protein coupling region in GPCRs, we have developed a computational method to calculate ligand bias ahead of experiments. We have validated the method for several ß-arrestin-biased agonists in ß2-adrenergic receptor (ß2AR), serotonin receptors 5-HT1B and 5-HT2B and for G-protein-biased agonists in the κ-opioid receptor. Using this computational method, we also performed a blind prediction followed by experimental testing and showed that the agonist carmoterol is ß-arrestin-biased in ß2AR. Additionally, we have identified amino acid residues in the biased agonist binding site in both ß2AR and κ-opioid receptors that are involved in potentiating the ligand bias. We call these residues functional hotspots, and they can be used to derive pharmacophores to design biased agonists in GPCRs.


Subject(s)
Drug Design , Molecular Dynamics Simulation/trends , Receptors, G-Protein-Coupled/chemistry , Receptors, G-Protein-Coupled/metabolism , Adrenergic beta-2 Receptor Agonists/metabolism , Adrenergic beta-2 Receptor Agonists/pharmacology , Allosteric Regulation/drug effects , Allosteric Regulation/physiology , Binding Sites/drug effects , Binding Sites/physiology , Humans , Ligands , Protein Structure, Secondary , Protein Structure, Tertiary , Receptors, Adrenergic, beta-2/chemistry , Receptors, Adrenergic, beta-2/metabolism , Receptors, G-Protein-Coupled/agonists , Receptors, Opioid, kappa/agonists , Receptors, Opioid, kappa/chemistry , Receptors, Opioid, kappa/metabolism
14.
Eur J Pharmacol ; 819: 89-97, 2018 Jan 15.
Article in English | MEDLINE | ID: mdl-29183838

ABSTRACT

This study describes the association rate and residence time of abediterol, a novel long-acting ß2-adrenoceptor agonist (LABA) in Phase II development for treatment of asthma and COPD, in comparison with indacaterol, olodaterol, vilanterol and salmeterol, for both human ß1- and ß2-adrenoceptors. Abediterol association and dissociation rates were monitored directly by using its tritiated form. Moreover, association was determined indirectly using experimental Ki and koff obtained from assays performed with unlabelled compound. Dissociation was also studied indirectly by measuring the association rate of 3H-CGP12177 to beta adrenoceptors previously occupied by unlabelled compounds. Abediterol shows a fast association for the ß2-adrenoceptor (kon 1.4 × 107 ± 1.8 × 106M-1min-1) while its dissociation rate is between 30 and 64 times slower than that of the reference LABA compounds tested, with a residence time of 91.3 ± 13.3min (measured directly) and 185.5 ± 7.5min (measured indirectly). Abediterol shows kinetic selectivity for the ß2- over the ß1-adrenoceptor, with a dissociation rate from the ß1-adrenoceptor similar to the other LABA compounds tested. In conclusion, abediterol is a potent LABA with a fast association rate and a long residence time at ß2-adrenoceptors. These data are in agreement with the onset and duration of action of abediterol shown in humans.


Subject(s)
Adrenergic beta-2 Receptor Agonists/metabolism , Adrenergic beta-2 Receptor Agonists/pharmacology , Quinolones/metabolism , Quinolones/pharmacology , Receptors, Adrenergic, beta-2/metabolism , Administration, Inhalation , Adrenergic beta-2 Receptor Agonists/administration & dosage , Humans , Kinetics , Quinolones/administration & dosage , Receptors, Adrenergic, beta-1/metabolism , Substrate Specificity
15.
Nat Commun ; 8(1): 1795, 2017 11 27.
Article in English | MEDLINE | ID: mdl-29176642

ABSTRACT

A complex conformational energy landscape determines G-protein-coupled receptor (GPCR) signalling via intracellular binding partners (IBPs), e.g., Gs and ß-arrestin. Using 13C methyl methionine NMR for the ß1-adrenergic receptor, we identify ligand efficacy-dependent equilibria between an inactive and pre-active state and, in complex with Gs-mimetic nanobody, between more and less active ternary complexes. Formation of a basal activity complex through ligand-free nanobody-receptor interaction reveals structural differences on the cytoplasmic receptor side compared to the full agonist-bound nanobody-coupled form, suggesting that ligand-induced variations in G-protein interaction underpin partial agonism. Significant differences in receptor dynamics are observed ranging from rigid nanobody-coupled states to extensive µs-to-ms timescale dynamics when bound to a full agonist. We suggest that the mobility of the full agonist-bound form primes the GPCR to couple to IBPs. On formation of the ternary complex, ligand efficacy determines the quality of the interaction between the rigidified receptor and an IBP and consequently the signalling level.


Subject(s)
GTP-Binding Protein alpha Subunits, Gs/metabolism , Receptors, Adrenergic, beta-2/metabolism , Signal Transduction , Single-Domain Antibodies/metabolism , Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Animals , Crystallography, X-Ray , GTP-Binding Protein alpha Subunits, Gs/chemistry , Ligands , Nuclear Magnetic Resonance, Biomolecular , Protein Conformation , Receptors, Adrenergic, beta-2/chemistry , Sf9 Cells , Single-Domain Antibodies/chemistry , Spodoptera
16.
Nature ; 547(7661): 68-73, 2017 07 06.
Article in English | MEDLINE | ID: mdl-28607487

ABSTRACT

G-protein-coupled receptor (GPCR)-mediated signal transduction is central to human physiology and disease intervention, yet the molecular mechanisms responsible for ligand-dependent signalling responses remain poorly understood. In class A GPCRs, receptor activation and G-protein coupling entail outward movements of transmembrane helix 6 (TM6). Here, using single-molecule fluorescence resonance energy transfer imaging, we examine TM6 movements in the ß2 adrenergic receptor (ß2AR) upon exposure to orthosteric ligands with different efficacies, in the absence and presence of the Gs heterotrimer. We show that partial and full agonists differentially affect TM6 motions to regulate the rate at which GDP-bound ß2AR-Gs complexes are formed and the efficiency of nucleotide exchange leading to Gs activation. These data also reveal transient nucleotide-bound ß2AR-Gs species that are distinct from known structures, and provide single-molecule perspectives on the allosteric link between ligand- and nucleotide-binding pockets that shed new light on the G-protein activation mechanism.


Subject(s)
GTP-Binding Protein alpha Subunits, Gs/metabolism , Receptors, Adrenergic, beta-2/metabolism , Single Molecule Imaging , Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Adrenergic beta-2 Receptor Agonists/pharmacology , Allosteric Site , Cell Membrane/metabolism , Clenbuterol/chemistry , Clenbuterol/metabolism , Clenbuterol/pharmacology , Enzyme Activation/drug effects , Epinephrine/chemistry , Epinephrine/metabolism , Epinephrine/pharmacology , Fluorescence Resonance Energy Transfer , GTP-Binding Protein alpha Subunits, Gs/chemistry , Guanosine Diphosphate/metabolism , Humans , Kinetics , Ligands , Models, Molecular , Movement/drug effects , Protein Stability , Receptors, Adrenergic, beta-2/chemistry
17.
Trends Pharmacol Sci ; 38(8): 717-732, 2017 08.
Article in English | MEDLINE | ID: mdl-28645833

ABSTRACT

Previously, drugs were developed focusing on target affinity and selectivity. However, it is becoming evident that the drug-target residence time, related to the off-rate, is an important parameter for successful drug development. The residence time influences both the on-rate and overall effectiveness of drugs. Furthermore, ligand binding is now appreciated to be a multistep process because metastable and/or intermediate binding sites in the extracellular region have been identified. In this review, we summarize experimental ligand-binding data for G-protein-coupled receptors (GPCRs), and their binding pathways, analyzed by molecular dynamics (MD). The kinetics of drug binding to GPCRs are complex and depend on several factors, including charge distribution on the receptor surface, ligand-receptor interactions in the binding channel and the binding site, or solvation.


Subject(s)
Receptors, G-Protein-Coupled/chemistry , Receptors, G-Protein-Coupled/metabolism , Adrenergic alpha-2 Receptor Antagonists/chemistry , Adrenergic alpha-2 Receptor Antagonists/metabolism , Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Analgesics, Opioid/chemistry , Analgesics, Opioid/metabolism , Humans , Kinetics , Ligands , Molecular Dynamics Simulation
18.
Angew Chem Int Ed Engl ; 56(31): 9008-9012, 2017 07 24.
Article in English | MEDLINE | ID: mdl-28481446

ABSTRACT

Protein nanobodies have been used successfully as surrogates for unstable G-proteins in order to crystallize G-protein-coupled receptors (GPCRs) in their active states. We used molecular dynamics (MD) simulations, including metadynamics enhanced sampling, to investigate the similarities and differences between GPCR-agonist ternary complexes with the α-subunits of the appropriate G-proteins and those with the protein nanobodies (intracellular binding partners, IBPs) used for crystallization. In two of the three receptors considered, the agonist-binding mode differs significantly between the two alternative ternary complexes. The ternary-complex model of GPCR activation entails enhancement of ligand binding by bound IBPs: Our results show that IBP-specific changes can alter the agonist binding modes and thus also the criteria for designing GPCR agonists.


Subject(s)
Receptors, G-Protein-Coupled/agonists , Single-Domain Antibodies/metabolism , Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Benzoxazines/chemistry , Benzoxazines/metabolism , Binding Sites , Drug Design , Epinephrine/chemistry , Epinephrine/metabolism , Humans , Ligands , Molecular Dynamics Simulation , Protein Binding , Receptors, Adrenergic, beta-2/chemistry , Receptors, Adrenergic, beta-2/metabolism , Receptors, G-Protein-Coupled/metabolism , Single-Domain Antibodies/chemistry , Thermodynamics
19.
J Agric Food Chem ; 65(13): 2867-2875, 2017 Apr 05.
Article in English | MEDLINE | ID: mdl-28322048

ABSTRACT

Salbutamol, a selective ß2-agonist, endangers the safety of animal products because of its illegal use in food animals. In this work, residues of salbutamol and its metabolites were investigated to select appropriate targets and marker residues for monitoring the illegal use of salbutamol. Ten metabolites of salbutamol were identified from plasma, urine, liver, and kidney samples; of these, six were newly identified. There were significant differences (P < 0.01) between the parent (nonconjugated) and total (conjugated + nonconjugated) salbutamol concentrations in plasma, urine, liver, and kidney tissues. Salbutamol residues in urine were relatively higher than those in plasma and other internal tissues during the dosing period and were rapidly eliminated from plasma, heart, spleen, and kidney tissues during the withdrawal time. Total salbutamol was identified as more preferable than parent salbutamol as a marker residue, and urine and eye tissues were found to be more suitable as targets for preslaughter and postslaughter monitoring of the illegal use of salbutamol in beef cattle.


Subject(s)
Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Agonists/metabolism , Albuterol/chemistry , Albuterol/metabolism , Drug Residues/chemistry , Drug Residues/metabolism , Adrenergic beta-2 Receptor Agonists/blood , Adrenergic beta-2 Receptor Agonists/urine , Albuterol/blood , Albuterol/urine , Animals , Cattle , Chromatography, High Pressure Liquid , Kidney/chemistry , Kidney/metabolism , Liver/chemistry , Liver/metabolism , Male , Mass Spectrometry
20.
Sci Rep ; 6: 34736, 2016 10 05.
Article in English | MEDLINE | ID: mdl-27703221

ABSTRACT

G protein-coupled receptors are recognized as one of the largest families of membrane proteins. Despite sharing a characteristic seven-transmembrane topology, G protein-coupled receptors regulate a wide range of cellular signaling pathways in response to various physical and chemical stimuli, and prevail as an important target for drug discovery. Notably, the recent progress in crystallographic methods led to a breakthrough in elucidating the structures of membrane proteins. The structures of ß2-adrenergic receptor bound with a variety of ligands provide atomic details of the binding modes of agonists, antagonists and inverse agonists. In this study, we selected four representative molecules from each functional class of ligands and investigated their impacts on ß2-adrenergic receptor through a total of 12 × 100 ns molecular dynamics simulations. From the obtained trajectories, we generated molecular fingerprints exemplifying propensities of protein-ligand interactions. For each functional class of compounds, we characterized and compared the fluctuation of the protein backbone, the volumes in the intracellular pockets, the water densities in the receptors, the domain interaction networks as well as the movements of transmembrane helices. We discovered that each class of ligands exhibits a distinct mode of interactions with mainly TM5 and TM6, altering the shape and eventually the state of the receptor. Our findings provide insightful prospective into GPCR targeted structure-based drug discoveries.


Subject(s)
Adrenergic beta-2 Receptor Agonists/metabolism , Adrenergic beta-2 Receptor Antagonists/metabolism , Receptors, Adrenergic, beta-2/chemistry , Receptors, Adrenergic, beta-2/metabolism , Adrenergic beta-2 Receptor Agonists/chemistry , Adrenergic beta-2 Receptor Antagonists/chemistry , Binding Sites , Crystallography, X-Ray , Humans , Ligands , Models, Molecular , Molecular Dynamics Simulation , Principal Component Analysis , Protein Binding , Protein Stability , Protein Structure, Secondary
SELECTION OF CITATIONS
SEARCH DETAIL
...